A pharmaceutical composition containing several different bacteria including Streptococcus thermophilus, Lactobacilli and bifidobacteria is disclosed. The bacteria are present in the composition at a total concentration of 1×1011 to 1×1013 per gram. Further, methods of using the pharmaceutical are disclosed which include treatment of a gastrointestinal disorder and hypercholestermia. Also a method for modulating a host's immune response is disclosed.
|
1. A pharmaceutical composition comprising:
a) from 10% to 95% by weight of total composition of lyophilized Streptococcus thermophilus, and
b) from 5% to 90% by weight of total composition of at least one lyophilized bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei, and
c) from 0% to 10% by weight of total composition a pharmaceutically acceptable excipient,
wherein said Streptococcus thermophilus and the bacterium b) are present in a concentration of 1×1011-1×1013 total bacteria per gram of the composition.
11. A method for treating hypercholesteremia, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein said Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
18. A method for treating a gastrointestinal disorder, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein aid Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
27. A method for modulating a host's immune response, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein said Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
9. A pharmaceutical composition comprising:
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of a mixture of lyophilized bifidobacteria; and
(g) from 8-10% by weight of a pharmaceutically acceptable excipient,
wherein all amounts are based on the total weight of the composition and said bifidobacteria is a mixture of bifidobacterium longum, bifidobacterium infantis, and bifidobacterium bifidum;
wherein said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose; and
wherein said Streptococcus thermophilus, said Lactobacillus casei, and said Lactobacillus plantarum are present in said pharmaceutical composition in a total concentration of 1×1011 to 1×1013 bacteria per gram.
2. The pharmaceutical composition of
3. The pharmaceutical composition of
4. The pharmaceutical composition of
5. The pharmaceutical composition of
6. The pharmaceutical composition of
7. The pharmaceutical composition of
8. The pharmaceutical composition according to
10. The pharmaceutical composition of
12. The method of
13. The method of
14. The method of
15. The method of
16. The method of
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of bifidobacterium longum, bifidobacterium infantis, and bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
17. The method of
19. The method of
20. The method of
21. The method of
22. The method of
23. The method of
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of bifidobacterium longum, bifidobacterium infantis and bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
24. The method of
28. The method of
29. The method of
30. The method of
31. The method of
32. The method of
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of bifidobacterium longum, bifidobacterium infantis, and bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
33. The method of
|
|||||||||||||||||||||||||||||||||||||||||
This application is a reissue of application Ser. No. 08/448,787, filed May 24, 1995, now U.S. Pat. No. 5,716,615, which is a continuation of application Ser. No. 08/117,751, filed on Sep. 8, 1993, now abandoned, which is a continuation-in-part of application Ser. No. 07/983,839, filed Dec. 1, 1992, now abandoned.
The present invention relates to dietary and pharmaceutical compositions useful for dietary or certain pharmaceutical indications, said composition containing lyophilized, lactic bacteria. Said compositions, being useful for prophylaxis or treatment of gastrointestinal disorders, or for treatment of hypocholesterolemia.
In Bifidobacteria Microflora, Vol. 3(1), 29-33, 1984, the beneficial effect of administering Bifidobacterium to patients suffering from leukemia is described. In FEMS Microbiology Reviews 46 (1987), 343-356, the therapeutical function of lactobacilli is disclosed, while Nobuo Suegara et al., Microecology and Therapy, Vol. 15, 271-280 (1985) state that oral administration of S. faecalis KAWAI greatly improves the lipid metabolism in human beings and animals. From Microecology and Therapy, Vol. 14, 109-126 (1984) the effect of streptococcus cell extracts on hyperlipemia in rats, rabbits and human beings is known. Other references describing the beneficial action of lactobacilli or other strains of activated lactobacilli are for example Bifidobacteria Microflora 1, 3-24, 1982 Recent Trends in Research on Intestinal Flora, Microecology and Therapy 14, 267, 1984 (Intestinal Flora Associated Endotoxin), Microecology Therapy 16, 271-272, 1986 (Bifidobacterium bifidum administration in Humans: a Controlled Clinical Study in Liver Cirrhosis), etc.
In Italian Patent No. 1,022,625 food and pharmaceutical compositions which stimulates the production of gamma-interferon and contain lactobacilli Streptococcus thermophilus and Lactobacillus bulgaricus are described.
In U.S. Pat. No. 4,806,368, Reddy envisaged the possibility of preparing dietary fiber based tablets with Lactobacillus acidophilus and/or Bifidobacterium bifidus, Leuconostoc citrovorum and Propionibacterium shermanii. To enhance the viability of L. acidophilus in the tablets, a combination of aminoacids, vitamins, calcium, magnesium salts, lactose and dietary fiber were included. The optimal concentration of lactobacilli in each 750 mg tablet was not higher than 1×107. High concentrations were avoided.
Fernandes et al. in their comprehensive review “Therapeutic role of dietary lactobacilli and lactobacillic fermented diary products,” published in FEMS Microbiology Reviews 46:343-356, 1987, indicate moreover the beneficial effects of lactobacilli, especially of L. acidophilus.
Takano et al., U.S. Pat. No. 4,913,913, describes a method for preparing a bifidobacteria-containing fermented milk, in which Lactobacilius casei and Bifidobacterium longum are cultivated in admixture or are mixed after being separately cultivated, and thus a bifidobacteria-containing lactic acid bacteria-fermented milk with an elevated survival rate of Bifidobacterium longum is obtained.
No suggestion is found in the literature to prepare a composition which combines several different lactic bacteria. In addition, there is no indication in the prior art to suggest administering to humans a concentration of lactobacilli exceeding 109 per gram.
It has now been found that a composition comprising at least two lactic acid bacteria strains allows improved therapeutical results to be achieved of a kind never previously attained by prior art compositions, provided that the concentration of each of two lactic bacteria strains exceeds 1011 viable lactic bacteria/gram of composition.
It is therefore an object of the present invention to provide an appropriate dietary and pharmaceutical composition comprising lyophilized lactic bacteria at high concentration per gram of product (>1011 bacteria/gram), qualitatively and quantitatively coordinated so as to be used for treatment or for prevention of certain gastrointestinal disorders, or for treatment or prevention of hypocholesterolemia or to potentiate the host's immune system. The composition of the present invention can be used in combination with any of a variety of compatible drugs.
The present composition can be used to antagonize the onset of diarrhea, constipation, hypercholesteremia, endotoxin absorption or production of endogenous toxic substances.
The compositions of the present invention comprise as essential active ingredients: (a) from 10 to 95% by weight of total composition of lyophilized lactic bacterium Streptococcus thermophilus, and (b) from 90 to 5% by weight of total composition of at least one further lyophilized lactic bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei. An excipient in an amount of from 1 to 10% by weight of total components can be added, said amounts being all based on the total weight of the composition. The composition can be used in combination with a compatible pharmaceutical in an amount of from 1 to 20% by weight based on the total weight of the composition. It is essential that the viable bacteria concentration be at least 1×1011 for (a) and 1×1011 for (b) per gram of the composition. Preferably, the viable bacteria concentration of both (a) and (b) should be used between 1×1011 and 1×1013 per gram of the composition.
The compositions of the invention can be prepared with methods well-known to those skilled in dairy technology, enabling the presence of viable bacteria at concentrations ranging between 1×1011 and 1×1013 bacteria per gram of the composition.
According to a preferred embodiment, the composition should also contain from 85 to 5% by weight of one or more lyophilized lactic bacteria selected from bifidobacteria (preferably a mixture of lyophilized Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium infantis, ratio of 1:1:1 by weight) at a concentration ranging between 1×109 and 1×1012 viable bacteria per gram of the composition, lyophilized Lactobacillus acidophilus at a concentration of from 1×109 to 1×1012 viable bacteria per gram of the composition, lyophilized lactobacillus delbruekii sub-species bulgaricus at a concentration of from 1×109 to 1×1012 viable bacteria per gram of the composition, and lyophilized Streptococcus faecium at a concentration of from 1×109 to 1×1012 bacteria per gram of the composition, optionally with 1 to 10% of an excipient and 1 to 20% of a compatible pharmaceutical.
A particularly preferred composition according to the present invention contains: a) 31% by weight of lyophilized Streptococcus thermophilus, 7×1011; b) 7% by weight of lyophilized Lactobacillus casei, 1×1011; c) 8% by weight of lyophilized Lactobacillus plantarum, 1×1011; d) 7% by weight of lyophilized Lactobacillus acidophilus, 2×1010; e) 8% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus, 3×109; f) 27% by weight of lyophilized bifidobacteria, 38×1010; and g) 12% by weight of an excipient, wherein all the amounts are based on the total weight of the composition and Bifidobacterium Bifidum, Bifidobacterium longum and Bifidobacterium infantis.
As mentioned above, as further optional components the compositions of the invention may contain usual excipients as are conventionally used for preparing pharmaceutical compositions in which normally the ratio of the active ingredient to the excipient will range between 1:10 and 99:90.
The compositions of the invention can be made in conventional pharmaceutical forms, such as for example tablets, coated tablets, capsules, packets, solutions, sachets, suspensions, emulsions, suppositories, pellets, syrups, vaginal suppositories, and are prepared in the usual m manner by mixing active ingredients in the mentioned amounts, eventually adding excipients and/or carriers, adjuvants and/or dispersing agents. Water may be used as the diluent. Organic solvents can be used in the form of adjuvants. Adjuvants can be for example, non-toxic organic solvents such as paraffines, vegetable oils (peanut oil or sesame oil), glycerine, glycols (propylene glycol, polyethylene glycol), solid carriers such as for example natural mineral flours (kaolin, talc), synthetic mineral flours (silicates for example), sugar (cane sugar for example), emulsifiers (alkylsulfonates or arylsulfonates and the like), dispersants (lignin, methylcellulose, starch and polyvinylpyrrolidone, for example) and lubricants (magnesium stearate, talc, stearic acid, sodium laurylsolfonate, for example). Preferred excipients for the composition of the invention are maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose and dextrose.
The administration takes place in the usual manner, preferably by oral route. In this case pharmaceutical forms adapted to this end can obtain, in addition to usual excipients, also additives such as sodium citrate, calcium carbonate, calcium dihydrogen phosphate, together with several additional substances such as starch, gelatin and the like. In case of liquid compositions compatible colouring agents of flavoring substances may be added.
As an optional component, the compositions may contain such compatible pharmaceuticals as anticholinergies, antihistamines, analgesics, adrenergics, antiinflammatories, antiseptics, hepatoprotective agents, or antilipemic drugs, in amounts of from 1 to 20% by weight, based on the total weight of the composition. As mentioned above, for preparing the compositions, the individual microorganisms in the dehydrated form are mixed in appropriate proportions and the mixture is then admixed with the excipients or optionally with other pharmaceuticals.
The following studies were carried out using a composition of lyophilized viable Streptococcus thermophilus and Lactobacillus plantarum, at concentrations respectively of 6×1011 and 4×1011 per gram of the composition.
The formulation of the preparation was in form of sachets, each containing 3 g of the composition. All the following studies were carried out in human health volunteers and in patients enrolled after informed consent according to the Helsinki declaration. Medical and laboratory controls were done by physicians aware of the good usual clinical practice (GPC) as stated by the European Economic Community (EEC). Statistical analysis was carried out by a statistician, not directly involved in the study. T0, T1, T2, and T3 refer respectively to pre-treatment, after one, two and three weeks of treatment.
In 33 patients affected by chronic hepatitis following C virus infection (anti-HCV+) the administration of one sachet per day (3 g of the composition containing 60% by weight of Streptococcus thermophilus and 40% by weight of Lactobacillus plantarum) induced a reduction of the aspartate aminostransferase (AST) from 52±32 IU at TO to 45±27 IOU at T2, of the alanine aminotransferase (ALT) from 68±39 IU at TO to 58±31 IU at T2 and of gamma-glutamyltranspeptidase (gGT) from 52±49 IU at TO to 40±25 IU at T2. In the above patients the following symptoms improved during and/or the treatment: anorexia, itching, nausea, diarrhea, constipation and insomnia. No undesired reactions or side-effects were noted. In 21 of the above patients, AST, ALT, and/or gGT resulted normalized at T3. As control group, 26 patients were treated with 15 capsules per day of Infloran Berna (trade mark), a marketed preparation of Bifidobacerium bifidum (1×109 bacterial per capsule) and Lactobacillus acidophilus (1×109 bacteria per capsule). The usual recommended daily dose of Infloran is 3 capsules per day; therefore the experiments were carried out administering a five fold increased dosage of Infloran. Apart from the poor compliance on the treated patients, no subject evidenced any significant variation in the AST, ALT and gGT levels at T3 (AST from 54±30 in AT to TO 55±31 IU; ALT from 65±34 IU at TO to 64±31 IU at T2 and gGT from 51±37 IU at TO to 55±41 IU at T2. The difference among the two groups was always statistically significant with p values <0.05.
In 24 subjects with serum cholesterol levels at TO of 268±126 mg/dl two sachets (6 gr per day of the composition comprising 68% by weight of Streptococcus thermophilus, 28% by weight of Lactobacillus casei and 4% by weight of maltodextrin) were administered, and at T3 the levels were reduced to 219±175 mg/dl (p<0.5). In the control group treated with 15 capsules of Infloran per day, the serum cholesterol levels did not change (from 254±156 mg/dl at TO to 250±168 mg/dl at T3)_.
Fifteen patients with irritable bowel syndrome were treated for 2 weeks with a sachet (3 g of the composition of Example 1) per day. Before and after the treatment colonscopy was performed and multiple endoscopic biopsies, at least 2 samples in each site, were taken in the descending and sigmoid colon. On biopsy specimens histological studies have shown a reduced number of infiltrating inflammatory cells. In the faeces of the same patients the measurement of tumor necrosis factor alpha has shown that the levels of this cytokine are reduced following the treatment with the preparation, from 45±12 pg/ml to faecal supernatant to 12±5 pg/ml (p<0.01).
In 18 healthy volunteers, the following parameters were evaluated before, during and at the end of the administration of one sachet (3 g) per day. In this study, the composition per gram was:
T0
T1
T2
T3
CHOLESTEROL (mg/dl)
average
190.6
179.0
174.4
184.2
Maximum
285.3
264.8
247.5
267.4
Minimum
108.3
118.1
108.6
113.6
SD
59.9
44.7
44.0
54.3
AST (IU/ml)
average
29.8
25.8
26.0
23.3
Maximum
97.3
88.1
81.5
59.1
Minimum
13.2
6.8
10.8
10.8
SD
23.1
22.0
19.1
13.7
ALT (IU/ml)
average
31.9
31.2
26.6
24.5
Maximum
131.6
132.6
99.1
91.0
Minimum
10.1
7.1
7.5
6.7
SD
34.5
35.4
26.3
24.1
gG T (IU/ml)
average
41.2
40.3
37.5
38.5
Maximum
127.0
137.8
129.1
125.6
Minimum
12.3
12.5
9.2
9.7
SD
34.3
37.1
35.4
34.3
NK Activity (12.5:1)
average
44.0
67.5
49.9
41.0
Maximum
62.0
97.0
62.0
56.0
Minimum
24.0
47.0
25.0
14.0
SD
12.2
16.9
11.4
14.1
NK Activity (25:1)
average
56.4
80.5
54.6
48.1
Maximum
66.0
100.0
69.0
63.0
Minimum
42.0
51.0
37.0
23.0
SD
9.8
13.3
9.5
12.0
NK Activity (50:1)
average
60.8
87.8
59.1
51.8
Maximum
74.0
100.0
65.0
63.0
Minimum
48.0
69.0
42.0
30.0
SD
7.5
10.5
6.9
11.1
CD4 TO CD8 CELL RATIO
average
1.45
1.75
1.64
1.27
Maximum
2.71
4.10
4.32
2.76
Minimum
0.96
1.05
0.97
0.58
SD
0.57
0.87
0.95
0.60
In the above subjects, fecal examination showed a mean increase of lactobacillus species from <1×106 colony forming units (CFU) per gram of fecal material to 64×106 CFU and of bifidobacteria species from <1×106 CFU to 68×106.
Strains used in the following formulation, given by way of example only, are as follows:
In order to obviate problems due to possible phage attacks, these strains can obviously be replaced by other cultures having the same features and origins, but provided with a different phage sensitiveness.
The individual strains maintained in a lyophilized and frozen form have been grown in synthetic media specific for each species. The fundamental component of the culture medium is permeate obtained by ultrafiltration of serum or milk, to which minimal amounts of biological activators are added depending on the species. After sterilization, the culture medium is inoculated with a strain per species or 1 to 3 strains belonging to the same genotype. Cultures have been incubated upon determination of optimal parameters for each strain: temperature, time, pH values and stirring.
Industrial cultures have been concentrated by centrifugation and lyophilization has been then carried out according to standard methodologies.
After lyophilization the cell mass has been pulverized under sterile conditions. The individual cultures submitted to chemical and microbiological tests have been maintained at 5° C. in hermetic vessels.
1) Streptococcus thermophilus (ATCC 19987)
Mother
The mother has been prepared by inoculating the strain in a medium consisting of 5% of permeate +1% of yeast extract and incubated at 44° C. over 3 hours.
Medium
Permeate
5%
Yeast extract
1%
Fermentation parameters
Fermenter:
72% 1 Applikon
Percent of inoculation:
1%
Incubation temperature
44° C.
Stirring speed
160 rpm
Neutralization set point
pH = 6.00
Neutralizing substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
3 h 30 m
Final cooling:
24° C.
Concentration parameters
Centrifuge type:
Westfalia SA1
Centrifugation temperature:
24° C.
flow rate:
24 l/h
(The concentrate was then centrifuged again using a
laboratory centrifuge at 6000 rpm over 20 minutes).
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector:
a solution of
lactose
Results: the number of microorganisms during the different steps of the process are reproduced in the following Table:
Steps
U.F.C./g
End of fermentation
2.4E9
Concentrate
1.6E11
Lyophilized
7.4E11
U.F.C. = Colony-forming units
E9 = one thousand millions
E11 = one hundred thousand millions
No particular problems have been found in the preparation of this microorganisms. Therefore the cell loss during the different steps of the process could be greatly limited and a high bacterial charge could be achieved in the lyophilized product.
2) Lactobacillus plantarum (ATCC 8289)
Mother
Prepared in MRS culture medium and incubated at 33° C. over 5 hours.
Medium
Permeate
5%
Yeast extract
1%
Glucose
2.5%
Fermentation parameters
Fermenter:
Applikon
Percent of inoculation:
1%
Incubation temperature
33° C.
Stirring speed
110 rpm
Neutralization set point
pH = 6.00
Neutralizing substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
15 h
Cell inactivation after fermentation by pasteurization at 80° C. over 15 minutes.
Concentration parameters
Centrifuge type:
Westfalia SA1
Centrifugation temperature:
60° C.
Flow rate:
40 l/h
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector:
a solution of
lactose
The number of microorganisms during the different process steps is reproduced in the following Table:
Steps
U.F.C.G
Count/g in
Thoma
End of fermentation
9.2E8
—
Lyophilized
—
1.0E11
U.F.C. = colony-forming units
E8 = one hundred millions
E11 = one hundred thousand millions.
3) Lactobacillus casei (ATCC 334)
Mother
Prepared in MRS culture medium and incubated at 37° C. over 8 hours and 30 minutes
Medium
Permeate
5%
Yeast extract
1%
Glucose
1%
Fermentation parameters
Fermenter:
Applikon
Inoculation percent:
1%
Incubation temperature
37° C.
Stirring speed
110 rpm
Neutralization set point
pH = 5.40
Neutralizing substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
15 h
Concentration parameters
Centrifuge type:
Westfalia SA1
Centrifugation temperature:
60° C.
Flow rate:
46 l/h
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector:
a lactose solution
Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps
U.F.C.G
Count/g in
Thoma
End of fermentation
1.0E9
—
Lyophilized
—
1.0E11
U.F.C. = Colony-forming units
E8 = one hundred millions
E11 = one hundred thousand millions.
4) Mixture of bifidobacteria (Bifodobacterium infantis (ATCC 15697)—Bifidobacterium longum (ATCC 15707)—Bifodobacterium bifidum (ATCC 35914), ratio 1:1:1 by weight)
Mother
The mother has been prepared by inoculating the strains in a medium consisting of 10% of powdered skimmed milk +0.5% of glucose +1% of yeast extract and incubated at 38° C. over 15 hours.
Medium
Permeate
4%
Yeast extract
1%
Bacto Soytone
0.25%
Glucose
0.5%
Fermentation parameters
Fermenter:
Applikon
Inoculation percent:
2%
Incubation temperature
38° C.
Stirring speed
110 rpm
Neutralization set point
pH = 6.00
Neutralizing substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
15 h
Cooling at the end of fermentation:
24° C.
Concentration parameters
Centrifuge type:
Westfalia SA1
Centrifugation temperature:
24° C.
Flow rate:
42 l/h
(The obtained concentrate has been then centrifuged again
with a laboratory centrifuge at 6000 rpm over 20 minutes)
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector: a solution of powdered skimmed milk+yeast extract+lactose+sodium maleate has been prepared.
Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps
U.F.C.G
End of fermentation
1.7E9
Concentrate
7.0E10
Lyophilized
3.8E11
U.F.C. = Colony-forming units
E9 = one thousand millions
E10 = ten thousand millions
E11 = one hundred thousand millions.
In this case too, in which bacteria are considered of “hard” growing, no particular problems have been found during the different preparation steps and the number of microorganisms is high both in the fermentation and on the lyophilized.
5) Lactobacillus acidophilus (ATCC 43121)
Mother
Prepared in a medium consisting of 5% of permeate+1% of yeast extract+1% of glucose+1% of Tween (Registered Trademark) 80 and incubated at 37° C. over 15 hours.
Medium
Permeate
5%
Yeast extract
1%
Glucose
1%
Tween (Registered Trademark) 80
0.1%
Fermentation parameters
Fermenter:
Applikon
Inoculation percent:
1%
Incubation temperature
37° C.
Stirring speed
110 rpm
Neutralization set point
pH = 6.00
Neutralizing substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
15 h
Cooling at the end of fermentation:
24° C.
Concentration parameters
Centrifuge type:
Westfalia SA1
Centrifugation temperature:
24° C.
Flow rate:
42 l/h
(The obtained concentrate has been then centrifuged again
with a laboratory centrifuge at 6000 rpm over 20 minutes)
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector: a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium maleate+Tween (Registered Trademark) 80. Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps
U.F.C./g
End of fermentation
2.9E8
Concentrate
2.3E10
Lyophilized
2.0E10
U.F.C. = Colony-forming units
E8 = one hundred millions
E10 = ten thousand millions
6) Lactobacillus delbrueckii sub-species bulgaricus (ATCC 7994)
Mother
Prepared in a medium consisting of 5% of permeate+1% of yeast extract+1% of beef extract+1% of glucose+0.1% of Tween (Registered Trademark) 80 and incubated at 44° C. over 4 hours and 30 minutes.
Medium
Permeate
5%
Yeast extract
1%
Beef extract
1%
Glucose
1%
Tween (Registered Trademark) 80
0.1%
Fermentation parameters
Fermenter:
Applikon
Inoculation percent:
1%
Incubation temperature
44° C.
Stirring speed
110 rpm
Neutralization set point
pH = 5.60
Neutralization substance type:
ammonium hydrate
(sol to 10%)
Fermentation time:
7 h
Cooling at the end of fermentation:
24° C.
Concentration parameters
Installation: pilot unit for Hydro Air Research
microfiltration with two serial ceramic diaphragms each
having a 0.2 m2 filtrating surface.
Microfiltration temperature
30° C.
Operating conditions
recirculation
flow rate 4000 l/h
input pressure
2.7 bar
output pressure
1.2 bar
average flow of
the permeate 30 l/h × m2
(The obtained concentration has been then centrifuged again
with a laboratory centrifuge at 6000 rpm over 20 minutes).
Lyophilization
Lyophilizer
Edwards MINI -
FAST 3400
Lyophilization protector: a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium glutamate+Tween (Registered Trademark) 80. Results: the number of micoorganisms during the different process steps is reproduced in the following Table:
Steps
U.F.C./g
End of fermentation
2.9E9
Concentrate
2.4E10
Lyophilized
3.5E9
U.F.C. = Colony-forming units
E9 = one thousand millions
E10 = ten thousand millions
| Patent | Priority | Assignee | Title |
| 10660857, | May 01 2009 | CHR HANSEN A S | Bacterial compositions for prophylaxis and treatment of degenerative disease |
| RE41276, | Mar 11 1996 | VSL Pharmaceuticals, Inc. | STRAINS OF BACTERIA AND PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE OF SUCH STRAINS AND USE OF SAME FOR PREVENTING AND TREATING DISEASES ASSOCIATED WITH OR CAUSED BY ALTERED METABOLISM OF BILE ACIDS |
| Patent | Priority | Assignee | Title |
| 4115199, | May 04 1977 | CHR HANSEN, INC | Preparation of culture concentrates for direct vat set cheese production |
| 4205132, | Jul 17 1978 | Microlife Technics, Inc. | Lyophilization of bacteria |
| 4226940, | Jan 23 1978 | Great Lakes Biochemical Co., Inc. | Non-frozen concentrated bacterial cultures |
| 4588595, | Nov 09 1982 | Morinaga Milk Industry Co., Ltd. | Culture containing a viable cell mass of Bifidobacteria and lactic acid bacteria |
| 4806368, | Sep 16 1987 | REDDY & REDDY INCORPORATED | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
| 4913913, | Feb 25 1987 | The Calpis Food Industry Co., Ltd. | Method of preparation of bifidobacteria-containing fermented milk |
| 5108766, | Oct 22 1990 | Flavorants for enhancing the taste and flavor of bakery products and process of making | |
| 5128260, | Jan 12 1989 | SYSTEMS BIO-INDUSTRIES, INC | Process for preparing culture concentrates for direct vat set dairy products production |
| 5143845, | Sep 03 1986 | Toa Pharmaceutical Co., Ltd. | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
| 5219597, | Feb 20 1991 | KOREA FOOD RESEARCH INSTITUTE | Method for producing highly concentrated, lactic-acid fermented product utilizing unground grainy rice and improving qualities thereof by the secondary, enzymatic treatment at fermentation |
| 5474932, | Jul 25 1991 | Probi AB | Intestine colonizing strains of lactobacilli |
| EP228881, | |||
| EP291578, | |||
| FR2609044, | |||
| IT1200625, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Date | Maintenance Fee Events |
| May 14 2009 | M2553: Payment of Maintenance Fee, 12th Yr, Small Entity. |
| Date | Maintenance Schedule |
| Jan 22 2011 | 4 years fee payment window open |
| Jul 22 2011 | 6 months grace period start (w surcharge) |
| Jan 22 2012 | patent expiry (for year 4) |
| Jan 22 2014 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 22 2015 | 8 years fee payment window open |
| Jul 22 2015 | 6 months grace period start (w surcharge) |
| Jan 22 2016 | patent expiry (for year 8) |
| Jan 22 2018 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 22 2019 | 12 years fee payment window open |
| Jul 22 2019 | 6 months grace period start (w surcharge) |
| Jan 22 2020 | patent expiry (for year 12) |
| Jan 22 2022 | 2 years to revive unintentionally abandoned end. (for year 12) |